Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Lumped-Parameter Cardiovascular Model for Investigating Hemodynamic Alterations During Atrial Fibrillation.

Bioengineering (Basel, Switzerland)·2026
Same author

PRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma.

Cell death & disease·2026
Same author

Targeting LIPA with ERX-41 Induces ER Stress and Inhibits Tumor Progression in Inflammatory Breast Cancer.

Biomolecules·2026
Same author

Comparison of radiolucent CFR-PEEK and titanium volar locking plates in distal radius fracture fixation.

Journal of orthopaedic surgery (Hong Kong)·2026
Same author

Gigobolins A-C, New Ophiobolins with Anticancer Activity from the Phytopathogenic Fungus <i>Drechslera gigantea</i>.

Journal of natural products·2026
Same author

Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer.

Oncogene·2026

Related Experiment Video

Updated: Jul 3, 2025

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

8.2K

Novel LIPA-Targeted Therapy for Treating Ovarian Cancer.

Alexia B Collier1, Suryavathi Viswanadhapalli1,2, Rahul Gopalam1

  • 1Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.

Cancers
|February 10, 2024
PubMed
Summary

This study reveals LIPA as a target for ovarian cancer (OCa) therapy. ERX-41, a novel agent, induces endoplasmic reticulum stress (ERS) to reduce OCa cell viability and tumor growth, offering a new treatment strategy.

Keywords:
ERX-41LIPAendoplasmic reticulum stresslysosomal acid lipase Aovarian cancer

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.3K

Related Experiment Videos

Last Updated: Jul 3, 2025

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

8.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Ovarian cancer (OCa) is a lethal gynecologic malignancy characterized by significant tumor heterogeneity, leading to therapeutic resistance.
  • Heightened basal endoplasmic reticulum stress (ERS) in OCa presents a potential vulnerability that could be exploited to overcome treatment resistance.
  • LIPA has been identified as a novel target for inducing ERS in cancer cells using the small molecule ERX-41.

Purpose of the Study:

  • To investigate the role of LIPA in OCa and evaluate the therapeutic potential of ERX-41 in treating this disease.
  • To determine if targeting LIPA-induced ERS can overcome OCa tumor heterogeneity and improve treatment outcomes.

Main Methods:

  • Expression analysis of LIPA in OCa tissues versus normal tissues using TNMplot, TCGA data, and immunohistochemistry.
  • In vitro assessment of ERX-41's effects on OCa cell viability, colony formation, and apoptosis.
  • Mechanistic studies to analyze ERS markers (CHOP, elF2α, PERK, ATF4) following ERX-41 treatment.
  • In vivo efficacy studies using xenograft and patient-derived xenograft (PDX) models of OCa.

Main Results:

  • LIPA is significantly overexpressed in OCa tissues compared to normal tissues.
  • ERX-41 treatment demonstrably reduced OCa cell viability and colony formation while promoting apoptosis.
  • ERX-41 robustly induced key markers of endoplasmic reticulum stress (ERS).
  • ERX-41 significantly inhibited tumor growth in both xenograft and PDX models.

Conclusions:

  • LIPA is highly expressed in ovarian cancer and serves as a viable therapeutic target.
  • ERX-41 effectively targets LIPA, inducing endoplasmic reticulum stress (ERS) and exhibiting potent anti-cancer activity in preclinical OCa models.
  • ERX-41 represents a promising novel therapeutic agent for ovarian cancer, potentially overcoming treatment challenges posed by tumor heterogeneity.